Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Memory expands neurotherapeutics alliance with Roche
The license grants rights to the drug class known as nicotinic alpha-7 receptor compounds; however it excludes rights to the intellectual property covering MEM 3454 which Memory is
The license grants rights to the drug class known as nicotinic alpha-7 receptor compounds; however it excludes rights to the intellectual property covering MEM 3454 which Memory is
Affecting more than one million people in the US, lupus erythematosus, commonly known as lupus or SLE, is an autoimmune disease that occurs when a person’s body is
Under the agreement Sanofi Pasteur may also provide pandemic vaccine to the Italian Ministry in the event of a pandemic being declared, once the actual virus strain responsible
The rodent models will carry selected genetic mutations and will be used for the validation of novel drug screening targets. Such targets are used to identify new compounds
The drug class, called pyrimidinediones, consists of unique compounds that possess two highly effective mechanisms of action against HIV; inhibition of reverse transcriptase (RT), and inhibition of virus
“Market approval for Zegerid Capsules is a significant milestone for Santarus, as it is the only immediate-release PPI (proton pump inhibitor) in a capsule form. Capsules and swallowable
The GSK vaccine has received approval in Europe before Merck & Co’s Rotateq, which is the only currently approved rotavirus vaccination in the US. In connection with the
The eight-week clinical trial compared three doses of teduglutide delivered by daily subcutaneous injection to a placebo. The study was designed to evaluate the drug’s safety and potential
The new 65,000 square foot facility will extend Eisai’s capability at the Research Triangle Park in North Carolina, and will encompass aseptic processing suites, laboratories and other support
The findings of Dr Charles Emerson, a senior scientist and director of the not-for-profit Boston Biomedical Research Institute (BBRI) and Dr Natalia Riobo, a postdoctoral fellow at the